Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:AEGR's 30-Y Financials

Financials (Next Earnings Date: 0)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

AEGR Guru Trades in Q1 2016

Jim Simons 776,429 sh (+516.70%)
Paul Tudor Jones 62,300 sh (+172.05%)
John Paulson Sold Out
» More
Q2 2016

AEGR Guru Trades in Q2 2016

Jim Simons 1,369,500 sh (+76.38%)
Paul Tudor Jones 93,100 sh (+49.44%)
» More
Q3 2016

AEGR Guru Trades in Q3 2016

Jim Simons 1,716,200 sh (+25.32%)
Paul Tudor Jones Sold Out
» More
Q4 2016

AEGR Guru Trades in Q4 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AEGR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology  
Compare:AMEX:NBY, NAS:CFRX, OTCPK:ORGS, NAS:XOMA, OTCPK:NWBO, NAS:SNSS, OTCPK:PMCB, AMEX:ATNM, NAS:ECYT, NAS:RGLS, NAS:PLXP, NAS:EGLT, NAS:NTRP, OTCPK:ANTB, NAS:FLKS, NAS:OVAS, NAS:KMPH, AMEX:SYN, NAS:CUR, NAS:AQB » details
Traded in other countries:KYE.Germany,
Headquarter Location:USA
Aegerion Pharmaceuticals Inc is a biopharmaceutical company. The Company currently operates in one business segment focusing on the development and commercialization of its product, lomitapide.

Aegerion Pharmaceuticals, Inc. was incorporated in February 2005. The Company is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. The Company currently operates in one business segment focusing on the development and commercialization of its product, lomitapide. The product, lomitapide, received marketing approval, under the brand name JUXTAPID (lomitapide) capsules ("JUXTAPID"). It is an adjunct to a low-fat diet and other lipid-lowering treatments, including low-density lipoprotein ("LDL") apheresis where available, to reduce low-density lipoprotein cholesterol ("LDL-C"), total cholesterol ("TC"), apolipoprotein B ("apo B") and non-high-density lipoprotein cholesterol ("non-HDL-C") in adult patients with homozygous familial hypercholesterolemia ("HoFH"). Lomitapide is also approved for the treatment of HoFH in Norway, Iceland, Mexico and Canada. The Company also sells lomitapide, on a named patient basis, in Brazil and in a limited number of other countries outside the U.S. and the EU where such sales are authorized based on the U.S. or the EU approval. The Company also launched JUXTAPID in the U.S. The Company relies on a contract manufacturer to produce drug substance for lomitapide and another contract manufacturer for drug product for its clinical trials and for commercial supplies. It distributes JUXTAPID through a specialty pharmacy that distributes JUXTAPID directly to patients and, under limited circumstances, to other purchasers. The lomitapide patent portfolio consists of five issued U.S. patents and issued patents in Europe, Canada, Israel, Australia, New Zealand and Japan and pending applications in the U.S., Australia, Japan, Canada, India and South Korea, all of which have been licensed in a specific field. The Company competes with Regeneron Pharmaceuticals, Inc., in collaboration with Sanofi, Roche Holding AG, Pfizer Inc., Amgen Inc., and Alnylam Pharmaceuticals, Inc. The Company's operations are subject to federal, state and local level, the EU and other countries extensively regulations.

Ratios

vs
industry
vs
history

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history

More Statistics

Revenue (TTM) (Mil) $164.64
EPS (TTM) $ -5.98
Short Percentage of Float16.90%
52-Week Range $1.23 - 10.85
Shares Outstanding (Mil)29.55
» More Articles for NAS:AEGR

Headlines

Articles On GuruFocus.com
Stocks Reach 5-Year Lows Apr 11 2016 
Stocks Reach 5-year Lows Apr 04 2016 
Stocks Fall to 5-Year Lows Mar 28 2016 
Gilead Sciences Releases Impressive Results for Hepatitis C Drug Nov 12 2014 
Weekly CEO Buys Highlight: APD, OCUL, CNMD, OPK, AEGR Aug 04 2014 
Weekly CEO Buys Highlight: GEO, TRUE, BANC, AEGR, CLMS Jun 02 2014 
Three CEOs Reporting Large Insider Buys May 22 2014 
Four CEOs Reporting Large Insider Buys May 09 2014 
100 Stocks at All-Time Highs | 60 Dividend Stocks Below the Results Feb 19 2013 
My 3 Favorite Dividend Stocks at All-Time-Highs | Stock List Dec 27 2012 

More From Other Websites
Aegerion's Juxtapid Gets Pricing Authorization in Japan Nov 18 2016
Aegerion Pharmaceuticals, Inc. :AEGR-US: Earnings Analysis: Q3, 2016 By the Numbers : November 7,... Nov 07 2016
Aegerion (AEGR) Reports Narrower-than-Expected Loss in Q3 Nov 04 2016
QLT's (QLTI) Reports In-Line Q3 Loss, Merger in Focus Nov 02 2016
ETF’s with exposure to Aegerion Pharmaceuticals, Inc. : October 20, 2016 Oct 20 2016
ETF’s with exposure to Aegerion Pharmaceuticals, Inc. : September 27, 2016 Sep 27 2016
5 Stocks Insiders Love Right Now Sep 14 2016
7 Stocks Under $10 Making Big Up Moves Aug 24 2016
ETF’s with exposure to Aegerion Pharmaceuticals, Inc. : August 12, 2016 Aug 12 2016
Aegerion Pharmaceuticals, Inc. :AEGR-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11,... Aug 11 2016
Aegerion (AEGR) Q2 Loss Wider than Expected, View Intact Aug 10 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}